SPYGLASS PHARMA INC
SGPNASDAQ🏆 #2332 by market capUS Equity
$32.58▼ $0.28 (−0.85%)
Pre-market · at closeTrack SGP
Get earnings, price moves & breaking news on Telegram
24h▼ 0.8%
7d▲ 15.7%
14d▲ 35.1%
30d▲ 25.4%
ytd—
1y—
🏦Market Cap
$1.09B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $31.90 – $33.16
- 52-Week Range
- $17.06 – $33.47
- Volume (shares)
- 7,079
- Avg Volume (shares)
- —
- Shares Outstanding
- 33.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.37
- Dividend Yield
- —
SPYGLASS PHARMA INC
SGPFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout SPYGLASS PHARMA INC
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy5
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.